Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
2013
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer Statistics, 2021
2021 Standout
Multiple myeloma
2014
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1998 Standout
Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?
1993
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
2010
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
2004
Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis?
2012
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Acute graft-vs-host disease
2001
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome
2008
Neuroblastoma: biological insights into a clinical enigma
2003 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
1993 Standout
Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid
1999
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Myelodysplastic Syndromes
2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
2004
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
2013
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes
2004
Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation
2011
BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF
2003
Antibody therapy of cancer
2012 Standout
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
2007
Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS
2022 StandoutNobel
Prophylaxis with Fluoroquinolones for Bacterial Infections in Neutropenic Patients: A Meta-Analysis
1996
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
2013
Limiting dilution analysis of human T cells: a useful clinical tool
1990
‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*
2003 Standout
Graft-versus-host disease
2009 Standout
The pathobiology of mucositis
2004 Standout
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Systemic amyloidosis
2015 Standout
Pulmonary Complications in Adult Blood and Marrow Transplant Recipients
2005
Regulatory T cells in transplantation tolerance
2003 StandoutNobel
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
2020
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation
2000
Neuroblastoma
2007 Standout
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases.
1991
Monoclonal antibodies for the prevention and treatment of graft-versus-host disease
2003
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
2002
The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA
1998
Therapy with azanucleosides for myelodysplastic syndromes
2010
Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow
2003
Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity
1998
CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis
2015
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
2010
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion
2004
Impact of Previous Aspergillosis on the Outcome of Bone Marrow Transplantation
1998
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
2007
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
2006
Acute Myeloid Leukemia
2015 Standout
Human mesenchymal stem cells modulate allogeneic immune cell responses
2004 Standout
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
2015
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
2010
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
2010
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
2012
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
1998 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Toward the potential cure of leukemias in the next decade
2018
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Aspergillus fumigatusand Aspergillosis
1999 Standout
Bone Marrow NK1.1− and NK1.1+ T Cells Reciprocally Regulate Acute Graft versus Host Disease
1999
Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins
2009
Human Adipose Tissue Is a Source of Multipotent Stem Cells
2002 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation
2015 StandoutNobel
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
1997
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
2007
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Multiple Myeloma
2011 Standout
Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients
2005
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
1998 Standout
Works of Boris Labar being referenced
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
2008
Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.
2018
Prevention of gram-negative bacterial infection in granulocytopenic patients: a randomized study comparing oral norfloxacin with gentamycin.
1989
FC RIIIA and FC RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
2007
CD43 Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma
2009
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
2003
Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?
2003
An autopsy study of systemic fungal infections in patients with hematologic malignancies
1995
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors
2002
Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin’s Disease
2005
Trastuzumab in the treatment of advanced breast cancer: Single-center experience
2001
Relationship between differing volumes of bone marrow aspirates and their cellular composition.
1990
Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.
1989
Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
2009
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.
1996
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups
2008
Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant.
1992
Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.
1989
High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.
1989
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
2011
Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.
2007
Allogeneic bone marrow transplantation for ALL in Zagreb.
1989
Prostaglandin E2 for prophylaxis of oral mucositis following BMT.
1993
Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients
2004